Outsourced Pharma Capacity Update Videos - Cell & Gene
-
ProBio Capabilities Update October 2026: Cell & Gene Therapy
11/3/2026
In vivo CAR-T therapies could expand access and lower costs by eliminating ex vivo manufacturing. Robust CMC strategies, vector design, and analytics are key to accelerating clinical translation.
-
Andelyn Biosciences Capabilities Update October 2026: Cell & Gene Therapy
11/3/2026
Achieving commercial readiness for AAV gene therapies starts early. Prioritizing assay lock, process qualification, and supply chain security reduces risk and supports reliable patient supply.
-
Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy
3/24/2026
A global CDMO specializing in cell and gene therapies, offering end-to-end development, manufacturing, and testing services with over 25 years of expertise and personalized client support.
-
Lonza Capabilities Update March 2026: Cell & Gene Therapy
3/24/2026
A global CDMO outlines end-to-end capabilities in cell and gene therapy, mRNA, and microbial platforms, emphasizing scalability, innovation, and seamless development through commercial manufacturing.
-
Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy
3/24/2026
A translational CDMO approach integrates development, analytics, and GMP manufacturing to streamline cell and gene therapy advancement from early research through scalable clinical production.
-
Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy
3/24/2026
An integrated draw‑to‑thaw CDMO model connecting donor sourcing, development, GMP manufacturing, and cryogenic storage to streamline workflows, strengthen quality control, and speed clinical readiness.
-
ElevateBio Capabilities Update March 2026: Cell & Gene Therapy
3/12/2026
Learn how to embed process development expertise early and continuously to eliminate knowledge gaps, reduce risk, and ensure consistent, high-quality execution from transfer through manufacturing.
-
Andelyn Biosciences Capacity Update October 2025: Cell & Gene Therapy
10/17/2025
A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.